Coeptis Therapeutics Inc
NASDAQ:COEP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Coeptis Therapeutics Inc
Net Income (Common)
Coeptis Therapeutics Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Coeptis Therapeutics Inc
NASDAQ:COEP
|
Net Income (Common)
-$21.3m
|
CAGR 3-Years
-233%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$21B
|
CAGR 3-Years
18%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.2B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$7.8B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$20.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
27%
|
CAGR 10-Years
24%
|
|
Coeptis Therapeutics Inc
Glance View
Coeptis Therapeutics, Inc. is a pharmaceutical company focused on the development of therapeutics and technologies to disrupt conventional treatment paradigms. The company is headquartered in Wexford, Pennsylvania and currently employs 4 full-time employees. The company went IPO on 2002-07-29. The Company, through its subsidiary, Coeptis Pharmaceuticals, Inc., is engaged in developing cell therapy platforms for cancer. Its product portfolio comprises CD38-GEAR-NK and CD38-Diagnostic. The firm's CD38-GEAR-NK is an autologous, natural killer (NK) cell-based therapeutic that is derived from a patient’s own cells and gene-edited to enable combination therapy with anti-CD38 monoclonal antibodies (mAbs). Its CD38-Diagnostic is an in vitro screening tool that is intended to provide the ability to pre-determine, which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as monotherapy or in combination with CD38-GEAR-NK.
See Also
What is Coeptis Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-21.3m
USD
Based on the financial report for Dec 31, 2023, Coeptis Therapeutics Inc's Net Income (Common) amounts to -21.3m USD.
What is Coeptis Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-233%
Over the last year, the Net Income (Common) growth was 43%. The average annual Net Income (Common) growth rates for Coeptis Therapeutics Inc have been -233% over the past three years .
